• Examples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries

      Guglielmetti, L; Hewison, C; Avaliani, Z; Hughes, J; Kiria, N; Lomtadze, N; Ndjeka, N; Setkina, S; Shabangu, A; Sikhondze, W; et al. (International Union Against Tuberculosis and Lung Disease, 2017-02-01)
      For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.
    • Outcomes From the First Multidrug-Resistant Tuberculosis Programme in Kenya

      Huerga, H; Bastard, M; Kamene, M; Wanjala, S; Arnold, A; Oucho, N; Chikwanha, I; Varaine, F (International Union Against Tuberculosis and Lung Disease, 2017-03-01)
      In March 2006, the first multidrug-resistant tuberculosis (MDR-TB) treatment programme was implemented in Kenya.
    • Patients' Costs Associated With Seeking and Accessing Treatment for Drug-Resistant Tuberculosis in South Africa

      Ramma, L; Cox, H; Wilkinson, L; Foster, N; Cunnama, L; Vassall, A; Sinanovic, E (International Union Against TB and Lung Disease, 2015-12)
      South Africa is one of the world's 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (R(R)-TB) and multidrug-resistant TB (MDR-TB) cases.